Loading...
Loading...
VNDA| Name | Value |
|---|---|
| Revenues | 52.6M |
| Cost of Revenue | 4.5M |
| Gross Profit | 48.1M |
| Operating Expense | 86.6M |
| Operating I/L | -38.5M |
| Other Income/Expense | 3.6M |
| Interest Income | 0.0M |
| Pretax | -34.9M |
| Income Tax Expense | -7.7M |
| Net Income/Loss | -27.2M |
Vanda Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes therapies for high unmet medical needs. The company's marketed products include HETLIOZ for non-24-hour sleep-wake disorders and Fanapt for schizophrenia. Their pipeline includes HETLIOZ for jet lag disorder, Smith-Magenis syndrome, and other conditions, as well as Fanapt for bipolar disorder. Additionally, they are developing Tradipitant for atopic dermatitis and other conditions, VTR-297 for hematologic malignancies, and VQW-765 for psychiatric disorders. Vanda Pharmaceuticals markets its products in the United States, Europe, and Israel.
